First look: how kidneys handle promising new Weight-Loss drug
NCT ID NCT06352411
Summary
This study tested how a new medicine called BI 456906, being developed for obesity and liver disease, behaves in people with different levels of kidney function. 42 adults, including people with no, mild, moderate, or severe kidney problems, received a single injection. Researchers tracked the drug levels in their blood and monitored their health for about two months to see if kidney issues change how the body processes the medicine.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRS Clinical Research Services Kiel GmbH
Kiel, 24105, Germany
-
CRS Clinical Research Services Mannheim GmbH
Mannheim, 68167, Germany
Conditions
Explore the condition pages connected to this study.